This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Adults who initially received the Johnson & Johnson’s (J&J) Janssen vaccine receive higher protection against severe COVID-19 if given a booster shot of an mRNA vaccine, according new research from the Centers for Disease Control and Prevention’s (CDC’s) VISION VE project. The data were gathered during the Omicron surge in the U.S., between December 2021 and March 2022.
The findings appear in a recent Morbidity and Mortality Weekly Report (MMWR): Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022. Westat staff among the coauthors include Duck-Hye Yang, Ph.D., Elizabeth A. Rowley, Dr.P.H.; Margaret Dunne, M.Sc., Patrick K. Mitchell, Sc.D., Jonathan (Jack) Davis, Ph.D., and Sarah W. Ball, Sc.D.
The data indicate the continued benefit of keeping vaccinations up to date to protect against severe disease and hospitalization.